GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells

Tivantinib has been described as a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET and is currently in advanced clinical development for several cancers including non-small cell lung cancer (NSCLC). However, recent studies suggest that tivantinib’s anticancer properties a...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Remsing Rix, Lily L., Kuenzi, Brent M., Luo, Yunting, Remily-Wood, Elizabeth, Kinose, Fumi, Wright, Gabriela, Li, Jiannong, Koomen, John M., Haura, Eric B., Lawrence, Harshani R., Rix, Uwe
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2013
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3944088/
https://ncbi.nlm.nih.gov/pubmed/24215125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/cb400660a
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk